Product logins

Find logins to all Clarivate products below.


Alexandr Ishkin, PhD

Principal Consultant for Discovery and Translational Science Consulting

Alex has over 15 years of experience as a science analyst in systems biology and bioinformatics, working with GeneGo and later Thomson Reuters and Clarivate. His key expertise is in network and pathway analysis of high-throughput molecular data sets, such as DNA-Seq, RNA-Seq, single-cell RNA-Seq, gene expression microarray, proteomics and metabolomics, in the context of drug development.
Alex is an expert in Clarivate’s products MetaBaseTM and CDDI. For over 10 years, he has been responsible for development and maintenance of Clarivate’s metabaseR package that enables efficient access to and bioinformatics analyses of the extensive MetaBaseTM content.

Alex is a program manager and principal software developer for two Clarivate-led precompetitive consortia, CBDD and ABC. The CBDD consortium (Computational Biology for Drug Discovery) was launched in 2013. Within the consortium, Alex developed a toolkit of over 70 advanced network analysis algorithms for drug discovery. Consortium members include Novartis, Pfizer, Sanofi, Roche, Merck, Janssen, Takeda, Boehringer Ingelheim, Eli Lilly, BMS, Abbvie, Biogen, UCB, Regeneron, and Daiichi Sankyo. The ABC (Algorithm Benchmarking Consortium) program is centered around benchmarking bioinformatics tools relevant for drug development research and has been running since 2021. Since its inception, the program helped customers to identify best-performing tools and practices across many areas of bioinformatics research.


arrow_forward
Get in touch with Alexandr

Latest news

Partner news August 17, 2026
ShanghaiRanking’s Academic Ranking of World Universities 2026 Press Release

The 2026 Academic Ranking of World Universities (ARWU) is released today by ShanghaiRanking Consultancy. Since 2003, ARWU has been presenting the world’s top universities annually based on transparent methodology and…

Partner news
News August 13, 2026
Clarivate and KYBORA Partner to Help Biopharma Companies Execute Strategic Transaction Outcomes

This collaboration combines the scientific and commercial expertise of Clarivate’s Life Sciences & Healthcare Consulting practice with KYBORA’s global transaction execution capabilities to accelerate life sciences transactions London, U.K., August…

News August 12, 2026
Clarivate Enhances SkyRiver to Help Libraries Share, Reuse and Create Trusted Metadata

Combining community metadata sharing, institutional choice and AI-powered record creation LONDON, UK, August 12, 2026 – Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the…

Related resources

Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
Blog June 24, 2026
Bringing oncology medicines to patients faster: How Clarivate R&D Consulting supports every step to approval
ADC Biopharma Biotech Bispecific antibodies BsAb Clinical trials Development Oncology Pharma R&D Regulatory Research
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Blog June 22, 2026
Using AI-powered translational safety intelligence to anticipate drug safety issues earlier
Biopharma Biotech Clinical trials CMC Development R&D Real-World Data Regulatory Research Safety
Three uncomfortable truths about cell and gene therapy in regulatory affairs Three uncomfortable truths about cell and gene therapy in regulatory affairs
Blog May 28, 2026
Three uncomfortable truths about cell and gene therapy in regulatory affairs
Consulting Resource Center Regulatory
How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.